Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Praxis Precision Medicines Inc (NASDAQ: PRAX) closed at $201.0 up 2.68% from its previous closing price of $195.76. In other words, the price has increased by $2.68 from its previous closing price. On the day, 0.53 million shares were traded. PRAX stock price reached its highest trading level at $206.36 during the session, while it also had its lowest trading level at $191.39.
Ratios:
For a deeper understanding of Praxis Precision Medicines Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.31. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $80.
H.C. Wainwright reiterated its Buy rating for the stock on March 03, 2025, while the target price for the stock was revised from $120 to $105.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 14 ’24 when Nemiroff Alex sold 8,239 shares for $80.20 per share. The transaction valued at 660,827 led to the insider holds 10,301 shares of the business.
Mastrocola Lauren sold 5,188 shares of PRAX for $424,318 on Nov 14 ’24. The Principal Accounting Officer now owns 5,613 shares after completing the transaction at $81.78 per share. On Nov 14 ’24, another insider, Mastrocola Lauren, who serves as the Officer of the company, bought 5,189 shares for $81.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRAX now has a Market Capitalization of 5002915840 and an Enterprise Value of 3929681920. For the stock, the TTM Price-to-Sale (P/S) ratio is 626.61 while its Price-to-Book (P/B) ratio in mrq is 10.46. Its current Enterprise Value per Revenue stands at 506.076 whereas that against EBITDA is -14.482.
Stock Price History:
The Beta on a monthly basis for PRAX is 3.00, which has changed by 1.941607 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, PRAX has reached a high of $205.89, while it has fallen to a 52-week low of $26.70. The 50-Day Moving Average of the stock is 157.41%, while the 200-Day Moving Average is calculated to be 257.18%.
Shares Statistics:
For the past three months, PRAX has traded an average of 790.25K shares per day and 1266050 over the past ten days. A total of 24.19M shares are outstanding, with a floating share count of 22.77M. Insiders hold about 5.88% of the company’s shares, while institutions hold 97.83% stake in the company. Shares short for PRAX as of 1760486400 were 2611630 with a Short Ratio of 3.30, compared to 1757894400 on 2383700. Therefore, it implies a Short% of Shares Outstanding of 2611630 and a Short% of Float of 12.36.
Earnings Estimates
Current recommendations for the stock of the company come from 12.0 analysts. The consensus estimate for the next quarter is -$3.42, with high estimates of -$2.79 and low estimates of -$4.25.
Analysts are recommending an EPS of between -$12.47 and -$14.65 for the fiscal current year, implying an average EPS of -$13.51. EPS for the following year is -$12.91, with 12.0 analysts recommending between -$5.4 and -$19.17.
